Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Map Pharmaceuticals has presented positive data from an in-vitro study evaluating receptor pharmacology of MAP0004, an orally inhaled dihydroergotamine for the potential treatment of migraine, compared to intravenous DHE.
Subscribe to our email newsletter
In this receptor pharmacology study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV dihydroergotamine (DHE), but did not activate receptors associated with side effects frequently seen with IV dihydroergotamine. In addition, MAP0004 did not affect receptors that have a role in regulating pulmonary function.
MAP0004 is designed to be self-administered by patients at home via Map Pharmaceuticals’s proprietary Tempo inhaler. In Phase II studies with migraneurs and with asthmatics, treatment with MAP0004 was well-tolerated, with no serious adverse events reported.
Thomas Armer, chief scientific officer of Map Pharmaceuticals, said: “The selective binding of MAP0004 at receptors associated with migraine rather than those associated with side effects offers a mechanistic hypothesis for the favorable safety and efficacy profile of MAP0004 compared to IV DHE that we have observed in our initial clinical studies.”